74 related articles for article (PubMed ID: 11196536)
1. Autoantibodies to CTLA-4 enhance T cell proliferation.
Matsui T; Nishioka K; Kato T; Yamamoto K
J Rheumatol; 2001 Jan; 28(1):220-1. PubMed ID: 11196536
[No Abstract] [Full Text] [Related]
2. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases.
Matsui T; Kurokawa M; Kobata T; Oki S; Azuma M; Tohma S; Inoue T; Yamamoto K; Nishioka K; Kato T
J Immunol; 1999 Apr; 162(7):4328-35. PubMed ID: 10201965
[TBL] [Abstract][Full Text] [Related]
3. CTLA4Ig-induced linked regulation of allogeneic T cell responses.
Lee RS; Rusche JR; Maloney ME; Sachs DH; Sayegh MH; Madsen JC
Transplant Proc; 2001; 33(1-2):88-9. PubMed ID: 11266718
[No Abstract] [Full Text] [Related]
4. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease.
Kouki T; Sawai Y; Gardine CA; Fisfalen ME; Alegre ML; DeGroot LJ
J Immunol; 2000 Dec; 165(11):6606-11. PubMed ID: 11086105
[TBL] [Abstract][Full Text] [Related]
5. Induction of alloantigen-specific T cell tolerance through the treatment of human T lymphocytes with wortmannin.
Taub DD; Murphy WJ; Asai O; Fenton RG; Peltz G; Key ML; Turcovski-Corrales S; Longo DL
J Immunol; 1997 Mar; 158(6):2745-55. PubMed ID: 9058809
[TBL] [Abstract][Full Text] [Related]
6. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
Khattri R; Auger JA; Griffin MD; Sharpe AH; Bluestone JA
J Immunol; 1999 May; 162(10):5784-91. PubMed ID: 10229811
[TBL] [Abstract][Full Text] [Related]
7. Molecules that inhibit T-cell functions: cytochemical localization and shuttling.
Santoro G; Anastasi G; Saverino D; Puri C; Zarcone D; Tacchetti C; Ciccone E; Grossi CE
Eur J Histochem; 2000; 44(1):89-99. PubMed ID: 10868297
[TBL] [Abstract][Full Text] [Related]
8. T cell activation: you can't get good help.
Linsley PS
Nat Immunol; 2001 Feb; 2(2):139-40. PubMed ID: 11175808
[No Abstract] [Full Text] [Related]
9. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion.
Saverino D; Tenca C; Zarcone D; Merlo A; Megiovanni AM; Valle MT; Manca F; Grossi CE; Ciccone E
J Immunol; 1999 Jan; 162(2):651-8. PubMed ID: 9916682
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 regulates tolerance induction and T cell differentiation in vivo.
Walunas TL; Bluestone JA
J Immunol; 1998 Apr; 160(8):3855-60. PubMed ID: 9558090
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population.
Anderson DE; Bieganowska KD; Bar-Or A; Oliveira EM; Carreno B; Collins M; Hafler DA
Nat Med; 2000 Feb; 6(2):211-4. PubMed ID: 10655112
[TBL] [Abstract][Full Text] [Related]
13. Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA4-Ig.
Goodier MR; Londei M
Immunology; 2001 Jan; 102(1):15-23. PubMed ID: 11168632
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4: new insights into its biological function and use in tumor immunotherapy.
Egen JG; Kuhns MS; Allison JP
Nat Immunol; 2002 Jul; 3(7):611-8. PubMed ID: 12087419
[TBL] [Abstract][Full Text] [Related]
15. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.
Mihara M; Tan I; Chuzhin Y; Reddy B; Budhai L; Holzer A; Gu Y; Davidson A
J Clin Invest; 2000 Jul; 106(1):91-101. PubMed ID: 10880052
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies against T-Cell costimulatory molecules are produced in canine autoimmune diseases.
Khatlani TS; Ma Z; Okuda M; Inokuma H; Onishi T
J Immunother; 2003; 26(1):12-20. PubMed ID: 12514425
[TBL] [Abstract][Full Text] [Related]
17. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.
Moreland LW; Alten R; Van den Bosch F; Appelboom T; Leon M; Emery P; Cohen S; Luggen M; Shergy W; Nuamah I; Becker JC
Arthritis Rheum; 2002 Jun; 46(6):1470-9. PubMed ID: 12115176
[TBL] [Abstract][Full Text] [Related]
18. Local immunomodulation to promote co-stimulatory blockade.
Chahine AA; Stoeckert C; Lau HT
Clin Transplant; 1995 Jun; 9(3 Pt 2):215-8. PubMed ID: 7670166
[No Abstract] [Full Text] [Related]
19. The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease.
Green JM
Am J Respir Cell Mol Biol; 2000 Mar; 22(3):261-4. PubMed ID: 10696061
[No Abstract] [Full Text] [Related]
20. The CD28 and CTLA-4 receptor family.
June CH; Vandenberghe P; Thompson CB
Chem Immunol; 1994; 59():62-90. PubMed ID: 7945930
[No Abstract] [Full Text] [Related]
[Next] [New Search]
